HoxB9 Inhibitors
The class of HoxB9 inhibitors comprises chemicals that can indirectly modulate the activity of the HoxB9 protein. YK-4-279 inhibits the EWS-FLI1 transcription factor, which regulates HoxB9, leading to a decrease in HoxB9 expression and activity. LY294002 and Wortmannin are both inhibitors of PI3K, a component of the PI3K/Akt/mTOR pathway that HoxB9 is known to activate. By inhibiting PI3K, these chemicals can decrease the activity of HoxB9. Similarly, Rapamycin, an mTOR inhibitor, can also decrease HoxB9 activity by inhibiting the same pathway. PD98059 and U0126, which are MEK inhibitors, can dampen the Raf/MEK/ERK pathway. As HoxB9 is known to upregulate this pathway, these chemicals can decrease HoxB9 activity. Similarly, Sorafenib, a Raf kinase inhibitor, can decrease HoxB9 activity by reducing the downstream signaling of the Raf/MEK/ERK pathway. SP600125, a JNK inhibitor, can decrease HoxB9 activity by reducing the downstream signaling of the JNK pathway, which HoxB9 is known to activate.
SB203580 is a p38 MAPK inhibitor that can decrease HoxB9 activity by reducing the activation of the p38 MAPK pathway, which HoxB9 can enhance. ZD1839 (Gefitinib), Erlotinib, and Lapatinib are all EGFR tyrosine kinase inhibitors. These chemicals can decrease HoxB9 activity by inhibiting the EGFR pathway, which HoxB9 can enhance. Specifically, Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2, offering a broader inhibition of the signaling pathways that HoxB9 can activate. These chemicals represent different mechanisms of HoxB9 inhibition, acting on different pathways that HoxB9 is involved in. They demonstrate how versatile and complex the regulation of HoxB9 can be, as it is involved in multiple signaling pathways, and its activity can be modulated by a variety of different chemical inhibitors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can reduce the downstream signaling of the PI3K/Akt/mTOR pathway. HoxB9 is known to activate this pathway, so the inhibition of PI3K by LY294002 can decrease the activity of HoxB9. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can downregulate the PI3K/Akt/mTOR pathway. Given that HoxB9 activates this pathway, the inhibition of PI3K by Wortmannin can decrease HoxB9 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Given that HoxB9 activates the PI3K/Akt/mTOR pathway, the inhibition of mTOR by Rapamycin can decrease the activity of HoxB9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can dampen the Raf/MEK/ERK pathway. HoxB9 is known to upregulate this pathway, so the inhibition of MEK by PD98059 can decrease the activity of HoxB9. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can reduce the downstream signaling of the JNK pathway. HoxB9 is known to activate this pathway, so the inhibition of JNK by SP600125 can decrease the activity of HoxB9. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Given that HoxB9 can enhance the activation of the p38 MAPK pathway, the inhibition of p38 by SB203580 can decrease HoxB9 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a Raf kinase inhibitor that can reduce the downstream signaling of the Raf/MEK/ERK pathway. Given that HoxB9 enhances this pathway, the inhibition of Raf by Sorafenib can decrease HoxB9 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
ZD1839 (Gefitinib) is an EGFR tyrosine kinase inhibitor. HoxB9 can upregulate EGFR signaling, so the inhibition of EGFR by ZD1839 can decrease HoxB9 activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor. Given that HoxB9 can enhance the activation of the EGFR pathway, inhibition of EGFR by Erlotinib can decrease HoxB9 activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2. Given that HoxB9 can enhance the activation of the EGFR pathway, inhibition of EGFR by Lapatinib can decrease HoxB9 activity. | ||||||